130 Nasal nitric oxide increases in people with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor by Pioch, C., Graeber, S., Allomba, C., Busack, L., Fuhlrott, B., Schnorr, A., Halver, E., Rohmel, J., Zagkla, E., Yoosefi-Moridani, M., Troltzsch, L., Syunyaeva, Z., Tattersall-Wong, J., Thee, S., Tosolini, A., Ziegahn, N., Mall, M., Stahl, M.

Get full text

P042 Nasal nitric oxide increases in patients with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor by Pioch, C.O., Graeber, S.Y., Allomba, C., Busack, L.M., Fuhlrott, B., Schnorr, A., Halver, E., Roehmel, J., Zagkla, E., Yoosefi, M., Troeltzsch, L., Syunyaeva, Z., Tattersall-Wong, J., Thee, S., Tosollini, A., Ziegahn, N., Mall, M.A., Stahl, M.

Get full text

P22-03: Read-Across case study – from hypothesis to regulatory acceptance by Fuhlrott, J., Rohrig, R., Lohmann, B.

Get full text

P06-28: Preconditions for complete fulfillment of data requirements for distinct endpoints using in silico methods by Rohrig, R., Fuhlrott, J., Lohmann, B.

Get full text

P06-28: Preconditions for complete fulfillment of data requirements for distinct endpoints usingin silicomethods by Rohrig, R., Fuhlrott, J., Lohmann, B.

Get full text

P08-15: Practical consequences of ECHA's advice on dose level selection for reproductive toxicity studies by Lohmann, B., Fuhlrott, J., Rohrig, R., Weber, M.

Get full text